




# Formulation Recommendation

## Effervescent Cough and Cold Tablet Using SPI Pharma's Effersoda®

Composition	% (By Weight)	mg / Tablet
1 Aspirin crystal - Rhodine 2080	10.16	325.00
2 Chlorpheniramine Maleate	0.06	2.00
3 Dextromethorphan HBr	0.31	10.00
4 Phenylephrine	0.24	7.80
5 Effersoda	37.22	1191.04
6 Anhydrous citric acid - crystal	26.20	838.40
7 Sorbigem SD 250	12.50	400.00
8 Calcium silicate	0.20	6.40
9 Natural Orange Flavor	1.23	39.36
10 Povidone 25	1.00	32.00
11 Sucralose	0.75	24.00
12 PEG 8000	10.00	320.00
13 DC simethicone	0.10	3.20
14 (85%) Docusate sodium compound w/(15%) Sodium benzoate	0.03	0.80
<b>Final Tablet Weight</b>		<b>3200.00</b>



### General Tablet Characteristics

Effervescent Tablet with Aspirin	Tablet Hardness (kP)	Tablet Thickness (mm)	Effervescent Time (sec.)
<b>Average</b>	8.3	5.22	80.8

### Method

1. Weigh the components individually and screen using a #20-mesh sieve. Mix ingredients 1-11 in an 8-qt V-blender at 25rpm for 15 minutes.
2. Weigh and screen the lubricant ingredients (12-14) and mix with the blend for an additional 5 minutes at 25rpm.
3. Compress the formulation to 3.2g tablets on a rotary tablet press outfitted with 0.9375" FFBE type "D" punches, operated at 25rpm, to a tablet hardness of 8.3kP.

### Your Partner for Formulating Success

Americas  
SPI Pharma, Inc.  
Rockwood Office Park  
503 Carr Rd., Suite 210  
Wilmington, DE 19809

T 302 576 8600  
800 789 9755 Ext. 8600  
F 302 576 8567

Europe/Middle East/ Africa  
SPI Pharma SAS  
Chemin du Vallon du Maire  
13240 Septemes-Les Vallons  
France

T 33 4 9196 3600  
F 33 4 9196 3633

Asia/Pacific  
SPI Pharma, Inc – India Branch  
21 B, Veerasandra Industrial Area  
Hosur Road, Bangalore – 560100  
Karnataka, India

T 91 80 3027 0005  
F 91 80 3027 0050

Australia Distribution Company  
Anzchem  
1 Braidwood Street  
Enfield NSW 2136  
Australia

T 61 2 9475 2200  
F 61 2 9475 2211

[www.spipharma.com](http://www.spipharma.com)



All trademarks are the property of SPI Pharma. Copyright SPI Pharma 2013. The information contained in this document is proprietary to SPI Pharma and may not be used or disseminated inappropriately. The information and recommendations contained herein are to the best of SPI Pharma, Inc.'s knowledge reliable and accurate. Any recommendations are made without warranty, either implied or expressed, due to the variations in equipment, conditions, and methods which may be used in commercially processing the products. No warranties of any kind are made, express or implied, including those of merchantability and fitness for particular purpose, other than the products conform to current standard specifications. SPI Pharma, Inc. makes no warranty that the use of the products or formulations provided by SPI Pharma, Inc. will not infringe any trademark, trade name, copyright, patent or other rights held by any third party when used in customer's application. SPI Pharma, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damage.